Oral Micronized Progesterone FDA Approval History

1998 FDA Approval: How Prometrium Reached the Market

The FDA granted approval to Solvay Pharmaceuticals for Prometrium (oral micronized progesterone) on October 29, 1998, under NDA 019781. The approval covered two specific indications: treatment of secondary amenorrhea and prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens.

Why Micronized Progesterone Was Different

Before Prometrium, the dominant progestogen in hormone therapy was medroxyprogesterone acetate (MPA), a synthetic progestin. Oral micronized progesterone offered a molecularly identical match to endogenous progesterone. The micronization process reduced particle size to improve gastrointestinal absorption, and suspension in peanut oil further enhanced bioavailability. This formulation delivered measurable serum progesterone levels within 2 to 4 hours of oral dosing [1].

The PEPI Trial's Role in Approval

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, published in JAMA in 1995, enrolled 875 healthy postmenopausal women across seven U.S. Clinical centers [1]. PEPI compared conjugated equine estrogens alone, conjugated equine estrogens with cyclic MPA, conjugated equine estrogens with continuous MPA, and conjugated equine estrogens with cyclic micronized progesterone (200 mg/day for 12 days per month). The micronized progesterone arm demonstrated effective endometrial protection: the rate of adenomatous or atypical hyperplasia was 0% in the micronized progesterone group over 36 months, comparable to both MPA regimens. PEPI also showed that micronized progesterone preserved the HDL-cholesterol benefit of estrogen therapy better than MPA did, with HDL increases of 4.1 mg/dL versus a 2.4 mg/dL decrease in the continuous MPA group [1].

Approved Dosing at Launch

The initial label specified 200 mg orally once daily at bedtime for 12 sequential calendar days per 28-day cycle for endometrial protection, and 400 mg orally once daily at bedtime for 10 days for secondary amenorrhea. The bedtime dosing instruction addressed the sedative and dizziness effects documented in key trials, where up to 33% of participants reported drowsiness [2].

Label Revisions: 2002 Through 2014

Prometrium's prescribing information has been revised multiple times since its initial approval. The most consequential changes followed the Women's Health Initiative (WHI) results and subsequent FDA class-wide actions on hormone therapy products.

The 2003 Boxed Warning

In January 2003, the FDA mandated a class-wide boxed warning for all estrogen and estrogen-plus-progestin products. This action followed the July 2002 early termination of the WHI estrogen-plus-progestin arm, which used MPA (not micronized progesterone) combined with conjugated equine estrogens in 16,608 women [3]. The WHI reported a hazard ratio of 1.26 (95% CI 1.00 to 1.59) for breast cancer and 2.11 (95% CI 1.58 to 2.82) for venous thromboembolism in the MPA-containing arm [3].

The Prometrium label received the same boxed warning despite the fact that the WHI did not study oral micronized progesterone. The warning stated that estrogens with progestins should not be used for the prevention of cardiovascular disease or dementia and should be prescribed at the lowest effective doses for the shortest duration consistent with treatment goals.

2014 Label Update

The FDA required a further label revision in 2014, incorporating updated safety language derived from the WHI Memory Study (WHIMS) data on dementia risk in women aged 65 and older. The revision also strengthened warnings about the difference between progesterone and synthetic progestins, noting that results from the WHI study using MPA should not be assumed to apply identically to other progestogen formulations [4].

Pregnancy and Lactation Labeling Rule Changes

In 2015, the FDA implemented the Pregnancy and Lactation Labeling Rule (PLLR), which replaced the old letter-category system (A, B, C, D, X). Prometrium's label was updated to remove the former "Category B" designation and include narrative summaries of available human data, animal data, and risk statements. The label now states that Prometrium is contraindicated in women with known or suspected pregnancy when used for hormone therapy indications [2].

Generic Approvals and Market Access

Generic oral micronized progesterone became available in the U.S. Starting in 2001, which significantly expanded patient access and reduced out-of-pocket costs.

Timeline of Generic Entries

Teva Pharmaceuticals received ANDA approval for generic micronized progesterone capsules (100 mg and 200 mg) in 2001. Watson Pharmaceuticals (now Actavis/Allergan) followed. By 2010, multiple generic manufacturers including Mylan, Sun Pharmaceutical, and Virtus Pharmaceuticals had entered the market [5]. The Drugs@FDA database lists more than a dozen approved ANDAs referencing the Prometrium NDA as of 2025.

Impact on Prescribing Volume

Generic availability drove a steep increase in prescribing. According to ClinCalc estimates based on IQVIA data, oral micronized progesterone ranked among the top 100 most prescribed medications in the U.S. By 2020. Wholesale acquisition cost for a 30-day supply of generic 200 mg capsules averaged $15 to $40, compared to approximately $180 to $250 for branded Prometrium before patent expiration.

Peanut Oil Formulation and Alternatives

All currently approved oral micronized progesterone capsules contain peanut oil as a solubilizing agent. The label carries a contraindication for patients with known peanut allergy. No peanut-oil-free oral micronized progesterone capsule has received FDA approval. Patients with peanut allergy may use compounded progesterone capsules (not FDA-approved) or vaginal micronized progesterone (Endometrin, approved 2007; or Crinone gel, approved 1997), which do not contain peanut oil [2].

Post-Market Safety Data: Progesterone vs. Synthetic Progestins

A growing body of observational research has distinguished the safety profile of micronized progesterone from that of synthetic progestins, particularly MPA.

Venous Thromboembolism

The E3N French cohort study, which followed 80,308 postmenopausal women from 1990 to 2002, found that transdermal estradiol combined with micronized progesterone carried no statistically significant increase in VTE risk (OR 0.9, 95% CI 0.6 to 1.5), while oral estrogen combined with synthetic progestins was associated with an OR of 3.9 (95% CI 2.3 to 6.7) for VTE [6]. These data, while observational, have influenced European prescribing patterns and guideline recommendations.

Breast Cancer Risk

The same E3N cohort reported that women using estrogen combined with micronized progesterone for up to 5 years showed no statistically significant increase in breast cancer risk (RR 1.00, 95% CI 0.83 to 1.22). By contrast, estrogen combined with synthetic progestins was associated with a relative risk of 1.69 (95% CI 1.50 to 1.91) [7]. The Endocrine Society's 2015 guideline on menopausal hormone therapy cited this evidence when noting the potential safety advantage of micronized progesterone over synthetic progestins.

FDA Sentinel System Monitoring

The FDA Sentinel System, a distributed data network covering over 100 million patients, has included oral micronized progesterone in ongoing post-market surveillance for hormone therapy products. Sentinel analyses evaluate real-world rates of stroke, VTE, breast cancer, and endometrial cancer among users of different progestogen formulations. As of the most recent publicly available Sentinel report, no new safety signals specific to oral micronized progesterone have been identified beyond the class-wide warnings already on the label [4].

Current Labeling: What the Prometrium Label Says in 2026

The most current Prometrium prescribing information, available through DailyMed and Drugs@FDA, reflects decades of accumulated safety and efficacy data.

Indications and Usage

Two FDA-approved indications remain unchanged from the original 1998 approval:

1. Prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women receiving conjugated estrogens tablets.
2. Treatment of secondary amenorrhea.

Boxed Warning Content

The current boxed warning covers three domains:

• Cardiovascular disorders and probable dementia: Estrogen-plus-progestin therapy should not be used to prevent cardiovascular disease or dementia, based on WHI and WHIMS substudy results.
• Breast cancer: The WHI estrogen-plus-MPA substudy reported increased breast cancer risk. The label notes that this finding may not apply to all progestogens.
• Prescribing guidance: Use the lowest effective dose for the shortest duration consistent with individual treatment goals and risks.

Key Warnings and Precautions

The warnings section addresses cardiovascular events (coronary heart disease, stroke, VTE), malignant neoplasms (breast cancer, endometrial cancer, ovarian cancer), probable dementia, gallbladder disease, visual abnormalities, and the peanut allergy contraindication. The label also warns about additive CNS-depressant effects when combined with alcohol or other sedating medications [2].

Pharmacokinetic Data on Label

After a single 200 mg oral dose, the label reports a Cmax of 17.3 ng/mL at approximately 2 hours (Tmax), with an elimination half-life of 16 to 18 hours. Steady-state concentrations during the 12-day cyclic regimen produce serum progesterone levels in the range of 5 to 15 ng/mL, which is sufficient for secretory transformation of the endometrium [2].

Guideline Endorsements and Off-Label Context

Multiple professional societies have endorsed oral micronized progesterone as the preferred progestogen for specific clinical scenarios.

The Endocrine Society

The Endocrine Society's 2015 Clinical Practice Guideline on treatment of symptoms of the menopause stated: "We suggest micronized progesterone rather than synthetic progestins for the progestogen component of hormone therapy, based on evidence of a more favorable risk profile for breast cancer and cardiovascular outcomes" (conditional recommendation, low-quality evidence) [8].

The North American Menopause Society

The 2022 NAMS Hormone Therapy Position Statement acknowledged the observational data favoring micronized progesterone for VTE and breast cancer risk relative to synthetic progestins, while noting that head-to-head randomized trial data remain limited. NAMS recommended individualized therapy selection based on patient risk factors, symptom severity, and preference [9].

Off-Label Uses

Clinicians frequently prescribe oral micronized progesterone off-label for luteal phase support in fertility treatment, cyclic therapy for abnormal uterine bleeding, and as part of gender-affirming hormone therapy for transgender women. These uses are not reflected on the FDA-approved label, and prescribing in these contexts relies on clinical judgment and society-specific guidelines such as those from the American Society for Reproductive Medicine [10].

Ongoing Regulatory Developments

Several regulatory and research developments may shape the future of oral micronized progesterone's label and market position.

Peanut-Free Formulation Efforts

At least two pharmaceutical companies have submitted INDs for peanut-oil-free oral micronized progesterone formulations using alternative lipid vehicles. No NDA or ANDA for a peanut-free capsule has been approved as of May 2026. If approved, such a product would address the labeled contraindication that currently excludes an estimated 1.8% of the U.S. Adult population with peanut allergy [2].

Potential Label Expansion

Researchers have called for FDA review of micronized progesterone's label to reflect accumulated evidence distinguishing it from MPA. A 2020 commentary in the Journal of Clinical Endocrinology & Metabolism argued that the class-wide boxed warning, driven by WHI data on a different drug, may discourage appropriate prescribing of micronized progesterone in women who would benefit from hormone therapy [8].

REPLENISH Trial Data

The phase 3 REPLENISH trial (N=1,835) studied a combined estradiol/progesterone capsule (TX-001HR, later approved as Bijuva in 2018) and generated additional safety and efficacy data for oral micronized progesterone at the 100 mg dose [11]. While Bijuva is a separate NDA product, its approval provided the FDA with contemporary endometrial safety data on micronized progesterone, reinforcing the 1998 PEPI-era evidence base.

The current recommended approach for postmenopausal women requiring progestogen therapy: confirm the clinical indication, select the lowest effective progesterone dose (typically 200 mg/day cyclically or 100 mg/day continuously), verify absence of peanut allergy, and prescribe at bedtime to minimize sedation-related adverse effects [2].